IMNN

0.53555.22%
DV

Douglas V. Faller

Chief Medical Officer

Dr. Douglas V. Faller, Ph.D., M.D., also known as Doug, has been the Chief Medical Officer of Imunon, Inc. since February 09, 2025. He had been Global Chief Medical Officer at Oryzon Genomics S.A. since March 2022 until 2024 and served as its Member of Scientific Advisory Board since 2024 until 2025 and serves as Member of Clinical Advisory Board - Oncology since 2025. Dr. Faller Co-founded HemaQuest Pharmaceuticals, Inc and serves as its Chairman of Scientific Advisory Board. Dr. Faller's research efforts have focused on the role of viruses and oncogenes in cancer and cell growth. He is an inventor of several of HemaQuest's technologies, including the discoveries related to viral-associated malignancies. He serves as Vice Chairman of the Department of Medicine and Professor of Medicine, Biochemistry, Pediatrics, Microbiology, Pathology and Laboratory Medicine. Dr. Faller directs national and institutional clinical trials in oncology, including 75 ongoing clinical trials. He was the scientific founder of Phoenicia Biosciences and Viracta Therapeutics until February 2025. Dr. Faller has been a Member of Scientific Advisory Board at BriaCell Therapeutics Corp. since May 31, 2017. Dr. Faller was associated with Takeda, where he was Executive Medical Director and Global Clinical Leader for more than 5 years. Dr. Faller served as first Director of Boston University Cancer Center where he was also Grunebaum Professor for Cancer Research and Professor of Medicine, Biochemistry, Pediatrics, Microbiology, Pathology and Laboratory Medicine. He serves as a Director of the Cancer Research Center at Boston University School of Medicine and Director of Cancer Programs at Boston Medical Center. He served as Vice-Chairman, Division of Medicine, of Boston University School of Medicine. He is a hematologist/oncologist, author of hundreds of scientific papers and recipient of numerous grants. He is an acknowledged expert in basic molecular and cellular biology of virus- and oncogene-transformed cells and tumors. He leads a translational research program which develops molecular cancer therapeutics derived from his basic research and tests them in clinical trials. He is the recipient of multiple awards and honors. He has multiple patents or patent applications for cancer therapeutics or diagnostics. He received post-graduate residency and subspecialty training in Hematology and Oncology at the University of California San Francisco, Boston Children's Hospital, Brigham and Women's Hospital, the Dana-Farber Cancer Institute and Harvard Medical School, where he was previously on the faculty in the Department of Medicine. Dr. Faller holds an M.D. from Harvard University and Ph.D. in Cancer Molecular Biology from the Massachusetts Institute of Technology.

公司職務